Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4489186 | 0.87 | HRH3 (0.34) | HRH3NOS3NOS1NOS2S1PR1 | |
| SCHEMBL18091474 | 0.79 | HRH3 (0.44) | HRH3NOS3NOS1NOS2S1PR1 | |
| SCHEMBL16263876 | 0.77 | S1PR1 (0.47) | HRH3NOS3NOS1NOS2S1PR1 | |
| SCHEMBL4492807 | 0.77 | HRH3 (0.42) | HRH3NOS3NOS1NOS2S1PR1 | |
| SCHEMBL2206093 | 0.77 | KEAP1 (0.50) | HRH3NOS3NOS1NOS2 | |
| SCHEMBL14967991 | 0.76 | NOS3 (0.37) | NOS3NOS1NOS2 | |
| SCHEMBL31370616 | 0.76 | HRH3 (0.45) | HRH3NOS3NOS1NOS2S1PR1 | |
| Hydrochloric Acid SCHEMBL4363063 | 0.76 | HRH3 (0.45) | HRH3NOS3NOS1NOS2DRD2 | |
| SCHEMBL30854439 | 0.75 | CYP1A2 (0.60) | HRH3NOS3NOS1NOS2DRD2 | |
| SCHEMBL19275192 | 0.74 | S1PR1 (0.53) | S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | claimed |
| EP-1409481-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-04 | — | — | EP | claimed |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | claimed |
| US-7501516-B2 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-03-10 | — | — | US | disclosed |
| EP-1409481-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-04 | — | — | EP | disclosed |
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2005-01-13 | — | — | US | disclosed |
| WO-2003047582-A1 | QUINOLINE DERIVATIVES AS ANTITUMOUR AGENTS | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009867-A1 | Quinoline derivatives and their use as tyrosine kinase inhibitors | ABL1, FLT3, JAK2 | HRH3 734/4885NOS3 542/4885NOS1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.